Smith+Nephew reported its strongest quarterly performance in two years to close 2025, signalling improving procedure volumes and sustained demand across core orthopaedic segments. Growth was driven by continued strength in sports medicine, reconstruction, and enabling technologies, where innovation and efficiency remain key factors influencing adoption. The company has continued investing in advanced surgical platforms and digital technologies designed to enhance precision, streamline workflow, and support more predictable outcomes. These results suggest increasing market stability following recent periods of uncertainty, as hospitals and ambulatory centres work through procedural backlogs while prioritizing technologies that improve value and operational performance. As orthopaedic companies compete on both innovation and clinical relevance, strong quarterly performance highlights the importance of balanced portfolios that address evolving surgeon needs. The positive trajectory underscores broader confidence in procedure recovery trends and continued investment in technologies aimed at improving efficiency, reproducibility, and patient outcomes across the orthopaedic landscape.